Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016

Institut Paoli-Calmettes602 enrolled

Overview

Unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients, aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016

The therapeutic results (response and survival) of young adult and adolescent patients with hematological malignancies are generally lower than those usually observed in adults over the age of 30, with equivalent treatment, particularly in lymphomatous pathology.The overall analysis of this large cohort of patients in its entirety, then by age groups (15-17 years, 18-25 years, 26-30 years) and pathology aims to describe the future of patients and patients. compare them to the results of the literature observed in this age group, and according to the therapeutic regimens administered (pediatric regimen or adult regimen).

Study Type

OBSERVATIONAL

Enrollment

602

Conditions

Malignant Haemopathies Acute Leukemia Non-hodgkin Lymphoma Hodgkin Lymphoma

Interventions

administered therapeutic regimensDRUG

administered therapeutic regimens

Eligibility

Sex: ALLMin age: 15 YearsMax age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Malignant hemopathies (acute leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma) in primary care between 2000 and 2016. Exclusion Criteria: * Not applicable

Locations (1)

Institut Paoli Calmettes

Marseille, Bouches Du Rhone, France

Outcomes

Primary Outcomes

Global Survival

delay between the date of diagnosis and the date of the latest news

Time frame: 15 years

Survival without event

delay between the date of diagnosis and an event (relapse, death, lost of follow-up)

Time frame: 15 years

Progression-free survival

defined as the delay between the date of diagnosis and the date of relapse or death.

Time frame: 15 years

Secondary Outcomes

Epidemiological distribution by pathology compared to the adult population over 30 years

Time frame: 1 day

Descriptive analysis of the characteristics of the disease at diagnosis by pathology

Time frame: 15 years

Descriptive analysis of treatments by pathology

Time frame: 15 years

Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology

Time frame: 15 years

Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.